Addex Pharmaceuticals Ltd said that it has achieved its first preclinical milestone in a licensing agreement with the Merck & Co affiliate, Merck Sharp & Dohme Research Ltd (MSD), for a candidate drug for Parkinson’s disease and other undisclosed indications, triggering a payment of $250,000.
